Abstract
Purpose To quantify spectral-domain optical coherence tomography (SD-OCT) images cross-sectionally and longitudinally in a large cohort of molecularly characterized patients with inherited retinal disease (IRDs) from the UK.
Design Retrospective study of imaging data.
Participants Patients with a clinical and molecularly confirmed diagnosis of IRD who have undergone macular SD-OCT imaging at Moorfields Eye Hospital (MEH) between 2011 and 2019. We retrospectively identified 4,240 IRD patients from the MEH database (198 distinct IRD genes), including 69,664 SD-OCT macular volumes.
Methods Eight features of interest were defined: retina, fovea, intraretinal cystic spaces (ICS), subretinal fluid (SRF), subretinal hyper-reflective material (SHRM), pigment epithelium detachment (PED), ellipsoid zone loss (EZ-loss) and retinal pigment epithelium loss (RPE-loss). Manual annotations of five b-scans per SD-OCT volume was performed for the retinal features by four graders based on a defined grading protocol. A total of 1,749 b-scans from 360 SD-OCT volumes across 275 patients were annotated for the eight retinal features for training and testing of a neural-network-based segmentation model, AIRDetect-OCT, which was then applied to the entire imaging dataset.
Main Outcome Measures Performance of AIRDetect-OCT, comparing to inter-grader agreement was evaluated using Dice score on a held-out dataset. Feature prevalence, volume and area were analysed cross-sectionally and longitudinally.
Results The inter-grader Dice score for manual segmentation was ≥90% for retina, ICS, SRF, SHRM and PED, >77% for both EZ-loss and RPE-loss. Model-grader agreement was >80% for segmentation of retina, ICS, SRF, SHRM, and PED, and >68% for both EZ-loss and RPE-loss. Automatic segmentation was applied to 272,168 b-scans across 7,405 SD-OCT volumes from 3,534 patients encompassing 176 unique genes. Accounting for age, male patients exhibited significantly more EZ-loss (19.6mm2 vs 17.9mm2, p<2.8×10-4) and RPE-loss (7.79mm2 vs 6.15mm2, p<3.2×10-6) than females. RPE-loss was significantly higher in Asian patients than other ethnicities (9.37mm2 vs 7.29mm2, p<0.03). ICS average total volume was largest in RS1 (0.47mm3) and NR2E3 (0.25mm3), SRF in BEST1 (0.21mm3) and PED in EFEMP1 (0.34mm3). BEST1 and PROM1 showed significantly different patterns of EZ-loss (p<10-4) and RPE-loss (p<0.02) comparing the dominant to the recessive forms. Sectoral analysis revealed significantly increased EZ-loss in the inferior quadrant compared to superior quadrant for RHO (Δ=-0.414 mm2, p=0.036) and EYS (Δ=-0.908 mm2, p=1.5×10-4). In ABCA4 retinopathy, more severe genotypes (group A) were associated with faster progression of EZ-loss (2.80±0.62 mm2/yr), whilst the p.(Gly1961Glu) variant (group D) was associated with slower progression (0.56 ±0.18 mm2/yr). There were also sex differences within groups with males in group A experiencing significantly faster rates of progression of RPE-loss (2.48 ±1.40 mm2/yr vs 0.87 ±0.62 mm2/yr, p=0.047), but lower rates in groups B, C, and D.
Conclusions AIRDetect-OCT, a novel deep learning algorithm, enables large-scale OCT feature quantification in IRD patients uncovering cross-sectional and longitudinal phenotype correlations with demographic and genotypic parameters.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work is primarily funded by a NIHR AI Award (AI_AWARD02488) which supported NP, WAW, MM, KB, SD and SM. The research was also supported by a grant from the National Institute for Health Research (NIHR) Biomedical Research Centre (BRC) at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology. NP was also previously funded by Moorfields Eye Charity Career Development Award (R190031A). BJ was partially funded by IIR-DE-002818 from Shire/Takeda and by the European Reference Network for Rare Malformation Syndromes, Intellectual and Other Neurodevelopmental Disorders (ERN-ITHACA). OAM is supported by the Wellcome Trust (206619/Z/17/Z). AYL is supported by an unrestricted and career development award from RPB, Latham Vision Science Awards, NIH OT2OD032644, NEI/NIH K23EY029246, and NIA/NIH U19AG066567. SA is supported by a scholarship from Qatar National Research Fund (GSRA6-1-0329-19010). SL is supported by a MRC Clinician Scientist Fellowship. This project was also supported by a generous donation by Stephen and Elizabeth Archer in memory of Marion Woods. The hardware used for analysis was supported by the BRC Challenge Fund (BRC3_027). We also gratefully acknowledge the support of NVIDIA Corporation with the donation of the Titan Xp GPU used for this research. The views expressed are those of the authors and not the funding organizations.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research was approved by the IRB and the UK Health Research Authority Research Ethics Committee (REC) reference (22/WA/0049) "Eye2Gene: accelerating the diagnosis of inherited retinal diseases" Integrated Research Application System (IRAS) (project ID: 242050). All research adhered to the tenets of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data that support the findings of this study are divided into two groups, published data and restricted data. Published data are available from the Github repository. Restricted data are curated for AIRDetect-OCT users under a license and cannot be published, to protect patient privacy and intellectual property. Synthetic data derived from the test data has been made available at https://github.com/Eye2Gene/.
Data availability
The data that support the findings of this study are divided into two groups, published data and restricted data. Published data are available from the Github repository. Restricted data are curated for AIRDetect-OCT users under a license and cannot be published, to protect patient privacy and intellectual property. Synthetic data derived from the test data has been made available at https://github.com/Eye2Gene/.
